Agios Pharmaceuticals | AGIO - Debt


Agios Pharmaceuticals reported $48.76M in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Agios Pharmaceuticals USD 48.76M 47.62M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amgen USD 54.59B 1.62B Sep/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
Astellas Pharma JPY 831.43B 83.94B Mar/2025
AstraZeneca USD 32.84B 1.19B Jun/2025
Bayer EUR 39.39B 1.31B Mar/2025
Biogen USD 6.29B 309.5M Sep/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Gilead Sciences USD 24.95B 6M Jun/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Incyte USD 42.41M 5.29M Jun/2025
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Moderna USD 741M 4M Jun/2025
Novartis USD 32.64B 1.37B Jun/2025
Novartis USD 32.02B 615M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025